Skip to content

Study · Not a test of the peptide alone · 1992

1 result

Spectral and sequence similarity between vasoactive intestinal peptide and the second conserved region of human immunodeficiency virus type 1 envelope glycoprotein (gp120): possible consequences on prevention and therapy of AIDS.

Veljkovic V, Metlas R, Raspopovic J, Pongor S

Biochemical and biophysical research communications1 Dec 1992Cited by 19 (Europe PMC)

PMID1472041 (opens in a new tab)DOI10.1016/0006-291x(92)92258-y (opens in a new tab)PepBankPUB-01472041
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01Computer modelNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn silicoOther

    Human vasoactive intestinal peptide showed spectral and sequence homology with the conserved peptide from HIV-1 gp120 that binds antibodies.

    In plain wordsVIP looks similar in sequence and spectrum to an HIV-1 protein fragment. This is a structure comparison, not a health result.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    Not applicableSpectral and sequence homology of VIP with HIV-1 gp120 conserved peptide
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Infection

    Source sentences

    Summary
    Here we reported striking spectral and sequence homologies between human vasoactive intestinal peptide (VIP) and the conserved peptide derived from HIV-1 gp120 which binds these antibodies.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.